# How Synthetic Data is Accelerating Innovation in Complex Environments
The artificial intelligence revolution has reached an inflection point where algorithms are abundant, computational power is accessible, yet one critical resource remains scarce: high-quality data. Traditional data collection methods struggle under the weight of privacy regulations, prohibitive costs, and the sheer difficulty of capturing rare events that AI systems must nonetheless handle. Enter synthetic data—artificially generated information that mimics real-world patterns without exposing sensitive details or requiring expensive field collection. This technology is transforming how organisations in healthcare, finance, automotive, and beyond develop intelligent systems. With Gartner predicting that 80% of AI training data will be synthetic by 2028, understanding how to generate, validate, and deploy these datasets has become essential for maintaining competitive advantage in increasingly complex operational environments.
Synthetic data generation techniques: GANs, VAEs, and Agent-Based modelling
The foundation of effective synthetic data lies in sophisticated generation techniques that can produce realistic, diverse datasets tailored to specific domains. Three primary methodologies have emerged as industry standards, each with distinct strengths depending on the application context and data characteristics required.
Generative adversarial networks for High-Fidelity medical imaging datasets
Generative Adversarial Networks (GANs) operate through an adversarial process where two neural networks—a generator and a discriminator—compete against each other. The generator creates synthetic samples whilst the discriminator attempts to distinguish them from real data. This iterative process continues until the generator produces samples indistinguishable from authentic data. In medical imaging, GANs have proven particularly valuable for generating realistic CT scans, MRI images, and histopathology slides that preserve the statistical properties of genuine patient data.
Research published in Nature Communications demonstrates that AI models trained on GAN-generated medical images can achieve comparable performance to those trained exclusively on real patient data. This breakthrough addresses a critical challenge in healthcare AI development: acquiring sufficient training examples of rare conditions without compromising patient privacy. A University of Michigan study found that increasing synthetic data realism through advanced GAN architectures improved AI model performance by up to 20% in certain computer vision tasks, highlighting the importance of generation fidelity.
Healthcare institutions like MDClone now leverage GAN-based synthetic data platforms to create statistically accurate patient records that mirror real clinical scenarios whilst eliminating re-identification risks. This enables researchers to explore complex questions—such as predicting disease progression or optimising treatment protocols—using datasets that behave like genuine patient populations without facing the legal and ethical hurdles of sharing sensitive information.
Variational autoencoders in financial transaction simulation
Variational Autoencoders (VAEs) offer a probabilistic approach to synthetic data generation, learning the underlying distribution of real data and sampling from this learned distribution to create new examples. Unlike GANs, VAEs provide a more stable training process and generate diverse outputs by design, making them particularly suitable for financial transaction data where capturing the full range of customer behaviours is essential.
Financial institutions employ VAEs to simulate transaction patterns for fraud detection model development. J.P. Morgan has explored synthetic data to improve fraud detection capabilities without relying on sensitive customer transaction records. Accessing and using real financial data typically requires costly anonymisation, compliance checks, and legal reviews that slow projects considerably. By generating synthetic datasets that replicate transaction patterns, organisations reduce the need for expensive data preparation whilst minimising regulatory hurdles, making AI projects faster, safer, and more cost-effective.
The architecture of VAEs proves especially valuable when dealing with highly regulated data environments. By encoding real transactions into a latent space representation and then decoding to generate synthetic examples, VAEs preserve statistical relationships between variables—such as correlations between transaction amounts, frequencies, and merchant categories—whilst ensuring no individual customer’s actual behaviour can be reconstructed from the synthetic output.
Agent-based modelling for autonomous vehicle training scenarios
Agent-based modelling (ABM) takes a fundamentally different approach by simulating complex systems through the interactions of autonomous agents following defined behavioural rules. For autonomous vehicle development, this means creating virtual environments populated with pedestrians, cyclists, other vehicles, and environmental factors that interact dynamically according to realistic physical and behavioural constraints.
Waymo reported simulating over 20 billion miles per day using agent-based approaches to test edge
miles in virtual environments to expose their autonomous driving stack to rare and hazardous situations that would be impractical—or unsafe—to capture in the real world. By varying agent behaviours, road layouts, weather conditions, and sensor noise, engineers can create rich synthetic datasets that stress-test perception, planning, and control algorithms at scale. This agent-based synthetic data allows teams to iteratively refine policies for tasks like lane changing, emergency braking, and pedestrian negotiation, dramatically accelerating learning cycles while reducing reliance on costly physical testing.
For organisations building autonomous systems, ABM offers a powerful way to explore “what if” scenarios. How does a robotaxi behave if three pedestrians suddenly cross at different speeds? What happens when an emergency vehicle appears from a blind junction in heavy rain? Because agent-based models are rule-driven, teams can encode local traffic laws, cultural norms, and even human error into the environment, resulting in synthetic datasets that better reflect the messy realities of complex urban ecosystems.
Privacy-preserving data synthesis using differential privacy mechanisms
As synthetic data adoption grows, so does scrutiny around privacy guarantees. While synthetic datasets do not contain direct copies of real records, poorly designed generators can inadvertently leak information about individuals in the training set. Differential privacy addresses this by introducing mathematically bounded noise during training or generation, limiting the influence any single record can have on the output.
In practice, this means applying mechanisms such as the Laplace or Gaussian mechanism to gradients or model parameters, governed by a privacy budget denoted as ε (epsilon). A smaller ε implies stronger privacy but may reduce utility, so organisations must balance risk tolerance with analytical needs. Recent work from leading cloud providers shows that differentially private synthetic data can retain high utility for tasks like segmentation and forecasting, while offering formal privacy guarantees that help satisfy GDPR, HIPAA, and other regulatory requirements.
For teams implementing privacy-preserving synthetic data pipelines, clear governance is essential. You need to define acceptable privacy budgets, document the mechanisms used, and routinely test for membership inference or re-identification risks. When combined with robust access controls and encryption, differential privacy transforms synthetic data from a “best effort” anonymisation approach into a defensible part of an organisation’s privacy-by-design strategy.
Overcoming data scarcity in regulated industries through synthetic datasets
Highly regulated sectors such as healthcare, banking, and biometrics often struggle with data scarcity—not because data does not exist, but because it cannot be easily shared or repurposed. Synthetic datasets offer a pragmatic way to break this deadlock, enabling innovation while staying within strict legal and ethical boundaries. By generating data that preserves statistical and structural properties without exposing real individuals, organisations can explore new use cases, test compliance scenarios, and collaborate across borders with far fewer constraints.
The key is alignment with sector-specific regulations and standards. Synthetic patient records must be GDPR-compliant, synthetic banking portfolios must support Basel III stress testing, and synthetic biometric traces must respect frameworks like BIPA in the US or similar regulations elsewhere. When designed thoughtfully, synthetic data becomes not just a workaround, but a strategic enabler for responsible AI in regulated environments.
Gdpr-compliant synthetic patient records in clinical trial design
Designing robust clinical trials requires extensive patient data to power feasibility studies, cohort selection, and endpoint modelling. Yet real electronic health records (EHRs) are tightly controlled under GDPR and national health regulations, limiting reuse and cross-institutional sharing. Synthetic patient records provide a way to simulate realistic trial populations, including comorbidities, medication histories, and lab trajectories, without processing identifiable health information.
For example, a pharmaceutical company can generate GDPR-compliant synthetic datasets that mirror disease prevalence, age distributions, and treatment patterns across multiple countries. Trial designers can then experiment with inclusion and exclusion criteria, estimate recruitment timelines, and predict dropout risks before engaging with real patients. This reduces costly protocol amendments and improves the likelihood that trials will recruit on time and deliver statistically robust outcomes.
To maintain compliance, organisations must ensure that synthetic trial datasets cannot be linked back to real individuals. This typically involves combining generative models (such as GANs or VAEs) with privacy safeguards like differential privacy or k-anonymity checks. Independent validation—by internal privacy offices or external auditors—adds further assurance that synthetic records meet GDPR’s requirements for data minimisation, purpose limitation, and protection against re-identification.
Basel III compliance testing with synthetic banking portfolio data
Banks operating under Basel III must demonstrate resilience to severe economic shocks through regular stress testing and scenario analysis. Yet using real customer data for these exercises raises confidentiality concerns and can limit the flexibility of simulations. Synthetic banking portfolio data offers a powerful alternative, enabling risk teams to model diverse macroeconomic conditions, credit events, and liquidity crises without touching live customer records.
By training generative models on historical loan, deposit, and trading book data, institutions can create synthetic portfolios that preserve key risk factors—such as probability of default, loss given default, and exposure at default—while removing any individually identifiable information. These synthetic portfolios can then be exposed to hypothetical shocks (for example, simultaneous property price collapse and interest rate spike) to estimate capital adequacy and liquidity coverage ratios under Basel III frameworks.
Because synthetic datasets are fully controllable, risk managers can oversample rare but critical events, like correlated corporate defaults or sudden funding dry-ups, to better understand tail risk. This leads to more robust internal models and richer documentation for regulators, demonstrating that the bank has tested not just historical scenarios but a wide range of plausible futures.
Fda-approved medical device validation using synthetic physiological signals
Developers of medical devices, particularly those incorporating AI algorithms, must demonstrate safety and efficacy to regulators such as the FDA. Gathering sufficient real-world physiological signals—ECG, EEG, PPG, or continuous glucose monitoring data—can be slow, expensive, and burdensome for patients. Synthetic physiological signals generated from mechanistic models or deep generative networks can augment limited real datasets, supporting more comprehensive validation.
For instance, simulation frameworks can generate synthetic ECG traces representing various arrhythmias, heart rates, and noise conditions. AI-enabled diagnostic devices can then be validated not only on real patient recordings but also on a broad spectrum of synthetic edge cases that may be rare in clinical practice. This helps demonstrate robust performance across demographics, comorbidities, and device artefacts, which regulators increasingly expect from AI-based medical products.
Regulatory acceptance hinges on transparency. Manufacturers must document how synthetic signals are generated, how closely they match real-world distributions, and how they are combined with real data in validation protocols. Encouragingly, recent FDA discussions and guidance on computer modelling and simulation for medical devices signal a growing openness to synthetic data—as long as its limitations are clearly understood and disclosed.
Synthetic biometric data for security system development under BIPA regulations
Biometric authentication systems—face recognition, fingerprint scanning, voice identification—depend on large datasets of biometric samples to achieve high accuracy and robustness. However, laws like the Illinois Biometric Information Privacy Act (BIPA) impose strict consent and usage requirements, making it risky to collect and reuse real biometric data at scale. Synthetic biometric datasets offer a compliant way to train and test these systems without infringing on individuals’ rights.
Using 3D morphable models, generative image models, or voice synthesis networks, organisations can produce synthetic faces, fingerprints, or speech patterns that mimic the variability of real populations without corresponding to actual people. These synthetic biometrics can be used to evaluate false acceptance and false rejection rates, test spoofing defences, and benchmark algorithm performance under challenging conditions such as low light or background noise.
To operate safely under BIPA and similar regulations, companies should treat even synthetic biometrics as sensitive. That means clearly separating them from any real biometric repositories, maintaining audit trails of how datasets are generated, and ensuring that commercial deployments are always validated on properly consented real-world data before going live. Synthetic data accelerates research and prototyping, but it does not remove the need for responsible governance.
Accelerating machine learning model training with synthetic data augmentation
While fully synthetic datasets can unlock new possibilities, many organisations gain the most value from using synthetic data as an augmentation layer on top of real data. By enriching training corpora with additional, carefully crafted examples, teams can reduce overfitting, address class imbalance, and expose models to rare or risky scenarios they might otherwise never encounter. The result is often a step-change in model robustness and generalisation—especially in complex environments.
Synthetic data augmentation is particularly powerful when combined with iterative model evaluation. You can think of it as a feedback loop: identify failure modes, generate synthetic examples that stress those weaknesses, retrain, and repeat. Over time, this targeted augmentation becomes a systematic way to harden models against edge cases, distribution shifts, and adversarial inputs.
Addressing class imbalance in fraud detection systems
Fraud detection is a textbook example of extreme class imbalance: genuine transactions vastly outnumber fraudulent ones, often by a ratio of thousands or even millions to one. Traditional oversampling techniques like SMOTE can help, but they may fail to capture the nuanced temporal and behavioural patterns that distinguish sophisticated fraud. Synthetic data generated with GANs or sequence models can create richer, more realistic fraudulent examples for training.
By learning from historical fraud cases, generative models can produce synthetic transactions that respect contextual dependencies—such as merchant type, time of day, geo-location, and device fingerprint—while exploring plausible variations. This helps classification models learn a more discriminative decision boundary, improving recall on rare fraud cases without dramatically increasing false positives. In one study, banks reported double-digit percentage improvements in detection rates after introducing synthetic fraud scenarios into their training pipelines.
From a practical standpoint, teams should treat synthetic fraud data as a living asset. As fraudsters evolve tactics, you can use newly detected patterns to retrain generators and expand the synthetic library of attacks. Combined with continuous monitoring and human-in-the-loop review, this approach supports an adaptive fraud detection system that keeps pace with adversaries rather than chasing them.
Reducing annotation costs in computer vision through procedural generation
Labelled images and videos are the lifeblood of computer vision, but manual annotation is expensive and time-consuming. Procedural generation—using simulation engines like Unity, Unreal Engine, or Blender—enables organisations to create vast numbers of synthetic scenes with perfectly accurate labels “for free.” Every object, pixel, and bounding box is known by construction, eliminating human labelling errors and dramatically reducing costs.
For example, a retailer developing an in-store analytics solution can procedurally generate thousands of synthetic store layouts with varied lighting, product placements, and customer behaviours. The engine automatically outputs segmentation masks, 3D poses, and tracking IDs, providing rich training data for tasks such as people counting, shelf-stock detection, or queue monitoring. Real-world images can then be used as a fine-tuning layer to close any remaining realism gap.
To maximise impact, teams should design procedural pipelines around diversity. Vary camera angles, materials, textures, and clutter levels to prevent models from overfitting to a narrow visual style. Think of it like a flight simulator for your computer vision model—the more varied the practice scenarios, the more confident you can be when deploying into messy, unpredictable real environments.
Edge case simulation for autonomous systems using CARLA and AirSim
Autonomous systems, from self-driving cars to delivery drones, often fail not in everyday conditions but in edge cases: unusual weather, sensor glitches, or rare combinations of obstacles. Open-source simulators like CARLA and Microsoft AirSim have become indispensable tools for generating synthetic edge case data at scale. They provide realistic physics, configurable sensors, and programmable environments that can be customised to reflect specific operational domains.
Using CARLA, for instance, engineers can script complex urban scenarios involving occluded pedestrians, erratic drivers, and rapidly changing traffic lights, then collect multi-sensor data (RGB, LiDAR, radar) with precise ground truth labels. Similarly, AirSim allows teams to test drone navigation under gusty winds, GPS dropouts, or rapidly changing terrain, all within a safe virtual sandbox. These synthetic datasets are invaluable for training and validating perception and control algorithms under conditions that would be dangerous or impractical to reproduce in the real world.
A disciplined workflow alternates between simulation and field testing. Start by training on a broad base of synthetic scenarios, validate on limited real-world data, then feed observed failure cases back into CARLA or AirSim by scripting analogous synthetic scenarios. Over time, this loop builds a robust library of edge cases that systematically hardens the autonomous stack, reducing the likelihood of catastrophic failures in production.
Synthetic data applications in healthcare: drug discovery and precision medicine
Healthcare is one of the most promising—and challenging—domains for synthetic data. On the one hand, high-quality clinical and molecular data is essential for breakthroughs in drug discovery and precision medicine. On the other, patient privacy, regulatory oversight, and data fragmentation make large-scale data sharing difficult. Synthetic datasets can bridge this gap by enabling collaborative research, advanced modelling, and personalised care planning without exposing sensitive patient information.
From virtual molecules to synthetic electronic health records and genomic profiles, healthcare organisations are increasingly using synthetic data to explore “what if” scenarios. What if we change a drug’s molecular scaffold? How might a treatment work in a rare disease cohort? How would an individual’s trajectory change under different care pathways? Synthetic data turns these questions into programmable experiments.
Molecular structure generation using SMILES notation and deep learning
In drug discovery, the search space of possible molecules is astronomically large. Deep learning models operating on SMILES (Simplified Molecular Input Line Entry System) notation—essentially a textual representation of molecular graphs—can generate novel molecular structures that resemble known compounds but explore new chemical territory. These models, often based on recurrent neural networks, transformers, or VAEs, act as powerful synthetic data generators for virtual screening.
By training on large libraries of existing molecules, generative models learn the grammar of valid chemistry: which atoms can bond, which substructures are common, and which modifications are likely to preserve stability or activity. Researchers can then steer generation towards desired properties, such as increased solubility, reduced toxicity, or higher binding affinity for a target protein. The result is a vast synthetic library of candidate molecules that can be triaged in silico before any wet-lab experiments are conducted.
Leading pharma companies now integrate these synthetic molecule generators into iterative design-make-test cycles. You can think of them as idea engines that continuously propose new candidates, informed by past experimental results. This synthetic data-driven approach compresses drug discovery timelines and reduces cost by focusing physical experiments on the most promising compounds.
Synthetic electronic health records for rare disease research
Rare diseases, by definition, affect small patient populations, making it difficult to assemble sufficiently large cohorts for robust statistical analysis or machine learning. Synthetic electronic health records (EHRs) offer a way to amplify limited real data by generating additional virtual patients that share similar clinical patterns. These synthetic EHRs may include diagnosis codes, medications, lab values, and longitudinal outcomes, all constructed to mirror real-world trajectories without revealing any actual patient’s identity.
Researchers can use synthetic EHR cohorts to explore disease progression models, simulate clinical trial recruitment, or train predictive models that estimate time to diagnosis or risk of complications. Because synthetic datasets are de-identified by design, they can be shared more freely across institutions and borders, accelerating collaborative research in areas where every additional insight matters.
To maintain scientific credibility, synthetic EHR generation must be grounded in domain expertise. Clinicians should validate that comorbidity patterns, treatment pathways, and outcome distributions make clinical sense, not just statistical sense. When done well, synthetic EHRs become a powerful tool to overcome the “small n” problem that has historically hampered rare disease innovation.
Digital twin technology in personalised treatment pathway modelling
Digital twins—virtual replicas of individual patients—are emerging as a cornerstone of precision medicine. By combining mechanistic models, machine learning, and synthetic data generation, digital twins can simulate how a specific patient might respond to different interventions over time. This allows clinicians to compare treatment strategies in silico before committing to a course of action in the real world.
For example, in oncology, digital twins can synthesise tumour growth trajectories, treatment responses, and toxicity profiles based on a patient’s genomic, imaging, and clinical data. Simulations can then explore alternative chemotherapy regimens, radiation schedules, or targeted therapies, helping to identify options that maximise efficacy while minimising side effects. The synthetic data generated by these simulations—hypothetical but grounded in real physiology—supports personalised shared decision-making between clinicians and patients.
Implementing digital twins at scale requires robust data infrastructure and governance. Organisations must ensure that underlying models are validated, that uncertainty is communicated transparently, and that synthetic simulations augment rather than replace clinical judgement. When those safeguards are in place, digital twins represent one of the most compelling applications of synthetic data for improving individual patient outcomes.
Synthetic genomic data for GWAS studies without privacy risks
Genome-wide association studies (GWAS) rely on large cohorts of genomic and phenotypic data to identify variants associated with diseases or traits. However, genomic data is uniquely identifying, and sharing it carries significant privacy risks, even after traditional anonymisation. Synthetic genomic datasets can mitigate this problem by generating artificial genomes that preserve allele frequencies, linkage disequilibrium patterns, and genotype-phenotype associations without reproducing any individual’s actual genome.
Researchers can use these synthetic cohorts for method development, pipeline benchmarking, or preliminary association analysis. For instance, new statistical models or polygenic risk score algorithms can be stress-tested on synthetic data across populations with varying ancestry mixes, without exposing sensitive real-world genomes. When promising methods emerge, they can then be validated on secured real datasets within controlled environments.
To ensure scientific accuracy, synthetic genomic generators often combine population genetics models with deep generative architectures. Careful validation is essential: synthetic data should reproduce key GWAS findings and population structure characteristics while failing standard re-identification tests. When those conditions are met, synthetic genomics offers a path to more open and collaborative research without compromising individual privacy.
Quality validation frameworks for synthetic datasets
As synthetic data permeates critical workflows, the question shifts from “can we generate it?” to “can we trust it?” Quality validation frameworks provide a structured way to answer that question. They assess whether synthetic datasets are statistically faithful to their sources, fit for specific downstream tasks, and free from artefacts or unintended biases. Without such frameworks, organisations risk deploying models trained on synthetic data that behaves well in the lab but fails in the wild.
An effective validation strategy spans three layers: statistical similarity, task-level performance, and robustness under adversarial scrutiny. Each layer offers a different lens on quality, and together they help teams decide when synthetic data is ready for production use—or when generation pipelines need further tuning.
Statistical fidelity metrics: wasserstein distance and maximum mean discrepancy
At the most basic level, synthetic data should resemble real data in terms of distributions, correlations, and higher-order structure. Metrics such as the Wasserstein distance and Maximum Mean Discrepancy (MMD) quantify how close two probability distributions are, providing objective measures of fidelity. While no single metric captures everything, they serve as useful starting points for comparing synthetic and real datasets.
For example, in a financial transaction dataset, teams might compute Wasserstein distances for marginal distributions like transaction amount and inter-transaction time, while using MMD to assess joint distributions across multiple features. If discrepancies are large, it signals that the generator is failing to capture key patterns, and retraining or architectural changes may be needed. Conversely, low distances across many dimensions provide evidence that synthetic data is a faithful stand-in for exploratory analysis and model training.
These metrics should be complemented with visual diagnostics—histograms, correlation heatmaps, and dimensionality reduction plots (like t-SNE or UMAP)—to catch issues that numbers alone might miss. Combined, they form a statistical “health check” that every synthetic dataset should pass before being used in high-stakes applications.
Domain-specific evaluation criteria in aerospace simulation data
Statistical similarity is necessary but not sufficient, especially in specialised domains like aerospace. Synthetic datasets used to train or validate flight control systems, fault detection algorithms, or maintenance predictors must also respect domain-specific physical and operational constraints. That means evaluating not just whether numbers line up, but whether synthetic scenarios are aerodynamically plausible and operationally meaningful.
For instance, synthetic flight trajectory data should obey basic physics: accelerations must be within structural limits, fuel burn must align with engine performance curves, and control surface deflections must fall within allowable ranges. Engineers may define custom metrics—such as adherence to flight envelopes, rate-of-climb profiles, or vibration spectra—that synthetic data must satisfy. In maintenance simulations, synthetic fault sequences must match realistic failure modes and maintenance schedules documented in historical records and OEM guidelines.
Embedding these checks into validation frameworks ensures that synthetic aerospace data does not inadvertently teach models to rely on impossible behaviours or artefacts. In safety-critical sectors, this level of domain-informed validation is non-negotiable; it is the difference between a helpful simulator and a misleading one.
Adversarial testing to detect synthetic data artefacts and biases
Even when synthetic data looks statistically sound, subtle artefacts or hidden biases can lurk beneath the surface. Adversarial testing—deliberately trying to break or distinguish synthetic data—helps surface these issues. One common technique is to train a classifier to distinguish real from synthetic samples. If it performs significantly better than random guessing, it suggests that generation artefacts remain and may leak into downstream models.
Another angle is to probe for fairness and bias. For example, teams can analyse model performance across demographic groups when trained on synthetic versus real data. If disparities widen under synthetic training, it may indicate that the generator is underrepresenting certain subgroups or exaggerating spurious correlations. In response, organisations can adjust training data, add fairness constraints, or modify architectures to produce more balanced synthetic outputs.
Adversarial red-teaming should be an ongoing process rather than a one-off gate. As generators, source data, or use cases evolve, new artefacts and biases can emerge. Treating synthetic data pipelines as first-class software products—with continuous testing, monitoring, and iterative improvement—helps ensure long-term reliability.
Enterprise implementation: synthetic data platforms and ROI analysis
For enterprises, the strategic question is no longer whether synthetic data is technically feasible, but how to industrialise it. Ad hoc experiments may prove value in isolated projects, but capturing organisation-wide benefits requires platforms, governance, and clear ROI metrics. The emerging synthetic data ecosystem spans commercial platforms, open-source frameworks, and bespoke internal tools, each with its own trade-offs in control, cost, and time-to-value.
Ultimately, the business case for synthetic data rests on measurable outcomes: faster model development, reduced compliance overhead, lower data acquisition costs, and improved performance in complex environments. To convince stakeholders, data leaders must move beyond anecdotes and quantify how synthetic data changes innovation velocity across portfolios of projects.
Commercial solutions: mostly AI, syntho, and gretel.ai platform comparison
Commercial synthetic data platforms such as Mostly AI, Syntho, and Gretel.ai aim to simplify generation, governance, and deployment for enterprise users. While each offers distinct features, they share common capabilities: connecting to existing data sources, training generative models, enforcing privacy constraints, and delivering synthetic datasets via APIs or self-service interfaces.
Mostly AI is known for its focus on structured enterprise data, offering strong support for banking, insurance, and telco use cases with built-in privacy controls and governance workflows. Syntho emphasises GDPR-compliant data synthesis with explainable quality reports, making it attractive for European healthcare and public sector organisations. Gretel.ai, by contrast, positions itself as a developer-friendly platform with robust APIs and open-source components, well-suited for teams that want to embed synthetic data generation directly into MLOps pipelines.
When evaluating platforms, enterprises should look beyond feature lists to consider integration effort, privacy certification, and domain expertise. Does the provider support your specific data types (for example, time series, logs, medical images)? Are there pre-built templates or accelerators for your industry? And how transparent is model training and validation, especially if you need to demonstrate compliance to regulators or auditors?
Open-source frameworks: SDV, synthea, and DataSynthesizer
Open-source frameworks provide a flexible, cost-effective route for organisations that prefer greater control over their synthetic data pipelines. The Synthetic Data Vault (SDV) ecosystem, for example, offers a suite of libraries for modelling relational, time series, and single-table data using a variety of generative models. It allows data scientists to experiment with different architectures and customise generation processes to their specific needs.
Synthea focuses on healthcare, generating realistic synthetic patient records, encounters, and clinical events based on publicly available models of disease progression and care pathways. It is widely used for testing health IT systems, training analytics models, and running proof-of-concept projects without accessing real patient data. DataSynthesizer, meanwhile, provides straightforward tools for generating differentially private synthetic datasets from tabular sources, making it a good starting point for privacy-conscious organisations.
The open-source route does require more in-house expertise. Teams must handle deployment, scaling, monitoring, and governance themselves. However, for organisations willing to invest, these frameworks can serve as building blocks for bespoke synthetic data platforms tailored to unique data landscapes and regulatory environments.
Quantifying innovation velocity through synthetic data adoption metrics
To sustain investment in synthetic data, enterprises need hard numbers that demonstrate impact. One useful concept is “innovation velocity”—how quickly an organisation can move from idea to validated prototype to production deployment. Synthetic data can accelerate each stage, but you must measure the effect. That means tracking metrics such as time-to-first-model, number of experiments per quarter, and percentage of projects blocked by data access issues.
For instance, a bank might find that projects using synthetic customer data for initial exploration reach a working prototype 30–50% faster than those waiting on traditional data provisioning. A healthcare provider might track how many research collaborations become feasible thanks to synthetic patient cohorts that bypass lengthy data-sharing negotiations. Over time, these metrics can be aggregated into dashboards that show the correlation between synthetic data adoption and business outcomes like reduced churn, improved risk prediction, or faster regulatory approvals.
Clear ROI analysis should also account for risk reduction. How many potential privacy incidents are avoided because teams use synthetic instead of real data in non-production environments? How much legal review time is saved? When we include these “avoided costs” alongside direct productivity gains, synthetic data emerges not just as a technical tool, but as a strategic lever for safer, faster innovation in complex environments.